Skip directly to content

CUA AND PFIZER CANADA AWARD TWO CLINICAL FELLOWSHIPS IN INCONTINENCE AND FOUR RECIPIENTS OF THE CUA-PFIZER UROLOGY RESIDENT GRANT PROGRAM IN ITS INAUGURAL YEAR

04/08/16

Researcher Drs. Henry Tran and Adiel Mamut are recipients of the 2016 fellowship program

The 2016 Canadian Urological Association and Pfizer Canada Clinical Fellowships in Incontinence have been awarded to two Canadian urologists who have just completed their urology residency; Dr. Henry Tran will be completing his fellowship at Columbia University [Department of Urology] and Dr. Adiel Mamut will be completing his fellowship at the Vesia [Alberta Bladder Centre] / Southern Alberta Institute of Urology [Division of Urology, Calgary]. With this funding, they will conduct new projects to improve support, education and treatment for patients with incontinence and functional urology.

Evaluation of Urodynamic Parameters on Outcomes following Surgical Treatment for Benign Prostatic Hyperplasia

Columbia University, Department of Urology researcher Dr. Henry Tran has been awarded one of two grants under the program, for a project that focuses on post-surgical treatment for patients with enlarged prostate for whom the anatomy and function of the bladder may be altered. “It is important to detect bladder underactivity because its presence might affect the efficacy of various surgical treatments for male stress urinary incontinence,” said Dr. Tran.  “The objectives of the research are to document the severity of bladder underactivity following surgical treatment of benign prostate hyperplasia and help predict treatment success in patients with bladder underactivity.”

Assessing the effectiveness and adverse effects of BoTN-A (Botox) in progressively elderly patients with overactive bladder

The second grant has been awarded to Dr. Adiel Mamut of Vesia [Alberta Bladder Centre] and the Southern Alberta Institute of Urology [Division of Urology, Calgary] who will conduct an observational study of the use of Botox (also called BoTN-A, a third line treatment) to treat overactive bladder (OAB) in progressively elderly patients (over the age of 65 years).

“Conducting this study will advance our understanding of the effects that Botox has on the elderly and, in turn, inform medical decisions with respect to treating these patients with this line of treatment,” said Dr. Mamut.

CUA-Pfizer Urology Resident Grant Program 2016 Winners

The CUA and Pfizer Canada have also awarded four grants to residents for their outstanding research or care enhancement projects that promote excellence in urology with the ultimate goal of improving patient care or further understanding the biology of urologic diseases.

Researcher

Project

Center

Jennifer Bjazevic

“Evaluating pain outcomes of caudal versus ilioinguinal nerve block in children undergoing unilateral groin surgery”

Department of Pediatric Surgery, Division of Pediatric Urology, University of Calgary

Alice Yu

“To determine whether the tumor immune infiltrate, as recently evaluated with the Immunoscore methodology, could be a useful prognostic marker in patients who underwent cystectomy for invasive bladder cancer. “

McGill University Health Centre Research Institute

 

Christopher J.D. Wallis

“Adjuvant versus salvage radiotherapy for patients with adverse prognostic features following radical prostatectomy: a decision analysis “

Sunnybrook Health Sciences Centre, Division of Urology

Madhur Nayan

“To evaluate whether exposure to putative antineoplastic medications is associated with kidney cancer specific survival and overall survival in patients diagnosed with kidney cancer.”

University of Toronto, Department of Surgery

 

About the CUA - Pfizer Canada Clinical Fellowship in Incontinence

The CUA-Pfizer Incontinence Fellowship Award provides much needed funding to support Canadian urologists that have completed their RCPSC training successfully and are embarking on clinical fellowships. The financial support for these fellowships will result in many of the brightest young urologists in Canada furthering their training in centers of excellence around the world in these areas of urology and bringing their advanced skill and knowledge set back to Canada. This will ultimately result in Canadians receiving the most comprehensive, innovative and contemporary care in incontinence.

“Urological disorders are a growing burden in Canada. These two awarded projects and the new grant program demonstrate a shared commitment by the CUA and Pfizer to ensure scientific discovery and innovation in the field of urology and specifically, incontinence,” says Dr. Jonathan Izawa, Chair of the Scientific Council of the Canadian Urological Association Scholarship Foundation (CUASF).

“We know that each patient experiences different challenges with incontinence,” says Dr. Vratislav Hadrava, Chief Medical Officer, Pfizer Canada Inc. “That is why programs such as these, which help improve the care and quality of life for people living with this condition are so important.  We are proud that through theses fellowships we are continuing to support Canadian urological researchers who are working to improve day to day life for people living with urinary incontinence.”

A fifth year with new fellowships will take place in 2017-2018. For more information on how to apply for 2017 grants, eligible research proposals, review criteria, notification dates and submission process please visit http://www.cua.org/en/training-scholarships.

About the CUA-Pfizer Urology Resident Grant Program

The CUA-Pfizer Urology Resident Grant Program is meant to support peer-reviewed competitive resident research or care enhancement projects that promote excellence in functional urology with the ultimate goal of improving patient care or further understanding the biology of urologic diseases. The financial support to Canadian urology residents may have great impact by allowing them to test novel hypotheses that established urologists might not have already considered.

About Canadian Urological Association

The Canadian Urological Association is a national member-based organization dedicated to enabling the profession to provide the highest possible standards of urologic care by collaboratively:

  • Fostering excellence in urologic practice through advocacy, education, research and practice support tools
  • Leading evidence-based clinical practice through the development of practice standards and guidelines
  • Providing continuous professional development for Canadian urologists along the career-path continuum
  • Providing leadership in public education for urologic conditions
  • Representing the Canadian urologic community in relationships with governments as well as national and international medical societies.

About Pfizer Canada

Pfizer Canada Inc. is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world’s best known and most prescribed medicines, infusion systems and vaccines. Pfizer’s ongoing research and development activities focus on a wide range of therapeutic areas following our guiding aspiration: Working together for a healthier world. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on Twitter (twitter.com/PfizerCA) or Facebook (facebook.com/Pfizer.Canada).
 

For further information:

Corporate Affairs Canada
Pfizer Canada Media Line: 1-866-9Pfizer (1 866 973-4937)
[email protected]